JAIDS: Journal of Acquired Immune Deficiency Syndromes

Articles Available on Medscape

• Outcomes Among HIV-Positive Patients Hospitalized With COVID-19
  What have we learned about the outcomes of hospitalized HIV patients co-infected with COVID-19? How do they differ from that of non-HIV patients?

  September 02, 2020

• HIV Testing and PrEP Use in a National Probability Sample of Sexually Active Transgender People in the United States
  HIV testing and pre-exposure prophylaxis are both effective methods of preventing the transmission of HIV, but how likely are transgender people to engage in these strategies?

  July 30, 2020

• Growth in Proportion and Disparities of HIV PrEP Use Among Key Populations Identified in the United States National Goals
  A better understanding of PrEP use disparities among key populations may help identify strategies to better target these vulnerable groups.

  July 16, 2020

• Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen
  What benefits might virologically suppressed HIV-positive patients obtain from switching to a darunavir/cobicistat-based ART regimen?

  July 01, 2020

• Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy
  Do women presenting for third-line ART experience different outcomes than men? A new study examines the gender disparities that may exist.

  May 29, 2020

• Raltegravir (RAL) in Neonates
  This study provides insight into the pharmacokinetics and safety of raltegravir in HIV-exposed neonates and discusses optimal dosing regimens.

  April 23, 2020

• PrEP Implementation Behaviors of Community-Based HIV Testing Staff
  How consistent are staff who provide community-based HIV testing in their PrEP implementation behaviors?

  March 30, 2020

• Darunavir Pharmacokinetics With an Increased Dose During Pregnancy
  A pharmacokinetic study investigates the use of an increased darunavir dose during pregnancy and the postpartum period. What are the impacts?

  March 13, 2020

• Estimates of Timely HIV Testing and Mortality Among HIV-Exposed Infants
  What strategies may help improve the timeliness of HIV testing among exposed infants?

  February 25, 2020

• Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States
  Is ibalizumab an effective and financially feasible therapeutic option for those with multidrug-resistant HIV?

  January 30, 2020

• Predictors of Viremia in Postpartum Women on Antiretroviral Therapy
  Which factors may be predictive of postpartum viremia among HIV-infected women on ART?

  December 24, 2019

• Incidence of HIV in a Nationwide Cohort Receiving Pre-Exposure Prophylaxis for HIV Prevention
  Although rare, incident HIV infections have been reported during PrEP use. What factors may account for these cases?

  December 02, 2019

• Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants
  Prophylactic nevirapine for the prevention of mother-to-child HIV transmission was not found to negatively affect growth outcomes among uninfected infants.

  November 15, 2019

• Use of Recommended Preventive Health Care Services and Variations in HIV Care Among Women With HIV in the United States, 2013-2014
  How likely are women to utilize preventive health services and routine visits for HIV care? What strategies may increase utilization among this group?

  October 31, 2019

• Development and Validation of HIV-ASSIST, an Online, Educational, Clinical Decision Support Tool to Guide Patient-Centered ARV Regimen Selection
  Is this newly developed decision support tool an effective approach to antiretroviral regimen selection?

  September 27, 2019

• Characteristics and Care Outcomes Among Persons Living With Perinatally Acquired HIV Infection in the United States, 2015
  Have treatment advancements and better access to care improved outcomes among those with perinatally acquired HIV infection?

  August 29, 2019

• Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial
  While ART has been very successful in preventing mother-to-child HIV transmission, data from the PROMISE trial indicates the association of ART with adverse pregnancy outcomes is strong.

  July 26, 2019

• Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir
  What have we learned about the safety of dolutegravir exposure during pregnancy?

  July 10, 2019

• Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy
  Is there an association between raltegravir exposure during pregnancy and the development of neural tube defects?

  July 02, 2019

• Detecting Disengagement From HIV Care Before It Is Too Late
  A newly developed screener of engagement in HIV care may help identify and support those patients at risk for disengagement.

  June 03, 2019